• Aptevo highlighted mipletamig in frontline AML with venetoclax-azacitidine, citing 81% CR/CRi and 65% CR in 31 patients.
• Safety update showed no cytokine release syndrome through Cohort 5 in the RAINIER dose-optimization study; more than 120 patients treated across trials.
• Development timeline targets recommended Phase 2 dose selection by year-end 2026; Phase 2 start in 1H27; first patient dosing in 2H27.
• Niowave collaboration set as a 50/50 effort to develop up to three radiopharmaceutical programs, starting with a Nectin-4/actinium-225 target.
• Pipeline emphasis included trispecific solid-tumor candidates such as APVO451; development candidate selection targeted by year-end 2026; IND-enabling studies in 1Q27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.